LeMaitre Vascular Inc (NASDAQ:LMAT) – Equities researchers at Barrington Research decreased their FY2018 earnings per share estimates for shares of LeMaitre Vascular in a research note issued to investors on Monday, October 8th. Barrington Research analyst M. Petusky now anticipates that the medical instruments supplier will post earnings per share of $1.02 for the year, down from their previous estimate of $1.07. Barrington Research currently has a “Outperform” rating and a $34.00 price target on the stock. Barrington Research also issued estimates for LeMaitre Vascular’s Q4 2018 earnings at $0.19 EPS, Q2 2019 earnings at $0.24 EPS, Q3 2019 earnings at $0.20 EPS, Q4 2019 earnings at $0.23 EPS, FY2019 earnings at $0.88 EPS and FY2020 earnings at $0.99 EPS.
LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Friday, October 5th. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.21. The business had revenue of $24.17 million during the quarter, compared to the consensus estimate of $26.06 million. LeMaitre Vascular had a return on equity of 19.49% and a net margin of 21.09%.
Other equities research analysts also recently issued reports about the company. Canaccord Genuity cut their price target on LeMaitre Vascular from $40.00 to $32.00 and set a “hold” rating for the company in a research note on Monday. Zacks Investment Research upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $32.00 price target for the company in a research note on Tuesday. Roth Capital downgraded LeMaitre Vascular from a “buy” rating to a “neutral” rating and boosted their price target for the company from $38.00 to $39.00 in a research note on Tuesday, October 2nd. ValuEngine downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Thursday, June 21st. Finally, BidaskClub downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, June 22nd. One analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the stock. LeMaitre Vascular currently has an average rating of “Hold” and a consensus target price of $35.63.
LeMaitre Vascular stock opened at $28.41 on Tuesday. The stock has a market cap of $748.16 million, a price-to-earnings ratio of 33.03, a PEG ratio of 2.42 and a beta of 0.63. LeMaitre Vascular has a 52-week low of $26.99 and a 52-week high of $41.28.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 6th. Investors of record on Tuesday, November 20th will be paid a dividend of $0.07 per share. The ex-dividend date of this dividend is Monday, November 19th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.99%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 32.56%.
In related news, Chairman George W. Lemaitre sold 39,820 shares of the business’s stock in a transaction that occurred on Friday, July 27th. The stock was sold at an average price of $37.34, for a total transaction of $1,486,878.80. Following the completion of the transaction, the chairman now directly owns 3,085,291 shares in the company, valued at approximately $115,204,765.94. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO George W. Lemaitre sold 22,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 25th. The shares were sold at an average price of $37.26, for a total value of $819,720.00. Following the transaction, the chief executive officer now owns 3,085,291 shares of the company’s stock, valued at $114,957,942.66. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 97,506 shares of company stock valued at $3,608,759. 20.30% of the stock is currently owned by corporate insiders.
Several large investors have recently made changes to their positions in LMAT. Northern Trust Corp boosted its stake in LeMaitre Vascular by 3.1% in the 2nd quarter. Northern Trust Corp now owns 256,951 shares of the medical instruments supplier’s stock worth $8,603,000 after purchasing an additional 7,700 shares during the period. Bank of New York Mellon Corp boosted its stake in LeMaitre Vascular by 3.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 246,444 shares of the medical instruments supplier’s stock worth $8,251,000 after purchasing an additional 7,177 shares during the period. Jane Street Group LLC bought a new position in LeMaitre Vascular in the 2nd quarter worth approximately $206,000. DF Dent & Co. Inc. bought a new position in LeMaitre Vascular in the 2nd quarter worth approximately $796,000. Finally, Tower Research Capital LLC TRC boosted its stake in LeMaitre Vascular by 222.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,451 shares of the medical instruments supplier’s stock worth $149,000 after purchasing an additional 3,072 shares during the period. Institutional investors own 79.75% of the company’s stock.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Recommended Story: Diversification For Individual Investors
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.